UBS Group’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.71M | Sell |
90,000
-10,000
| -10% | -$322K | ﹤0.01% | 4693 |
|
|
2025
Q4 | $3.12M | Hold |
100,000
| – | – | ﹤0.01% | 4524 |
|
|
2025
Q3 | $2.02M | Hold |
100,000
| – | – | ﹤0.01% | 4945 |
|
|
2025
Q2 | $1.68M | Buy |
+100,000
| New | +$1.61M | ﹤0.01% | 4990 |
|
|
2023
Q3 | – | Sell |
-50,000
| Closed | -$377K | – | 9959 |
|
|
2023
Q2 | $377K | Buy |
+50,000
| New | +$405K | ﹤0.01% | 5055 |
|
|
2021
Q4 | – | Sell |
-231,100
| Closed | -$2.25M | – | 10703 |
|
|
2021
Q3 | $2.25M | Sell |
231,100
-168,900
| -42% | -$1.58M | ﹤0.01% | 3479 |
|
|
2021
Q2 | $3.96M | Sell |
400,000
-7,300
| -2% | -$77.3K | ﹤0.01% | 2925 |
|
|
2021
Q1 | $4.7M | Sell |
407,300
-27,700
| -6% | -$318K | ﹤0.01% | 2668 |
|
|
2020
Q4 | $4.2M | Buy |
435,000
+90,000
| +26% | +$862K | ﹤0.01% | 2638 |
|
|
2020
Q3 | $3.11M | Hold |
345,000
| – | – | ﹤0.01% | 2646 |
|
|
2020
Q2 | $4.25M | Sell |
345,000
-800,000
| -70% | -$9.05M | ﹤0.01% | 2173 |
|
|
2020
Q1 | $10.3M | Sell |
1,145,000
-325,000
| -22% | -$3.33M | ﹤0.01% | 1392 |
|
|
2019
Q4 | $14.4M | Buy |
1,470,000
+675,000
| +85% | +$6.03M | 0.01% | 1627 |
|
|
2019
Q3 | $5.47M | Buy |
795,000
+20,000
| +3% | +$153K | ﹤0.01% | 2302 |
|
|
2019
Q2 | $7.15M | Buy |
775,000
+138,000
| +22% | +$1.66M | ﹤0.01% | 2031 |
|
|
2019
Q1 | $9.99M | Sell |
637,000
-187,200
| -23% | -$3.3M | ﹤0.01% | 1677 |
|
|
2018
Q4 | $12.7M | Buy |
824,200
+37,200
| +5% | +$763K | 0.01% | 1394 |
|
|
2018
Q3 | $17M | Buy |
787,000
+637,000
| +425% | +$14.8M | 0.01% | 1328 |
|
|
2018
Q2 | $3.65M | Sell |
150,000
-222,000
| -60% | -$4.53M | ﹤0.01% | 2616 |
|
|
2018
Q1 | $6.36M | Sell |
372,000
-4,714,500
| -93% | -$92.1M | ﹤0.01% | 2095 |
|
|
2017
Q4 | $96.4M | Buy |
5,086,500
+4,636,000
| +1,029% | +$69.7M | 0.04% | 422 |
|
|
2017
Q3 | $7.93M | Buy |
450,500
+199,900
| +80% | +$4.5M | ﹤0.01% | 1795 |
|
|
2017
Q2 | $8.32M | Buy |
250,600
+80,000
| +47% | +$2.48M | ﹤0.01% | 1700 |
|
|
2017
Q1 | $5.47M | Buy |
170,600
+52,100
| +44% | +$1.78M | ﹤0.01% | 2022 |
|
|
2016
Q4 | $4.3M | Sell |
118,500
-7,800
| -6% | -$311K | ﹤0.01% | 2235 |
|
|
2016
Q3 | $5.81M | Buy |
+126,300
| New | +$6.59M | ﹤0.01% | 1886 |
|
|
2016
Q2 | – | Sell |
-300,300
| Closed | -$16.1M | – | 7967 |
|
|
2016
Q1 | $16.1M | Buy |
300,300
+18,200
| +6% | +$1.07M | 0.01% | 1024 |
|
|
2015
Q4 | $18.5M | Buy |
282,100
+155,000
| +122% | +$9.58M | 0.01% | 1002 |
|
|
2015
Q3 | $7.18M | Buy |
127,100
+48,800
| +62% | +$3.16M | 0.01% | 1636 |
|
|
2015
Q2 | $4.63M | Sell |
78,300
-23,700
| -23% | -$1.46M | ﹤0.01% | 2152 |
|
|
2015
Q1 | $6.36M | Sell |
102,000
-851,200
| -89% | -$49.5M | ﹤0.01% | 1865 |
|
|
2014
Q4 | $54.8M | Buy |
+953,200
| New | +$53.1M | 0.04% | 499 |
|
Other funds holding TEVA
HIIFS
PF
MMH
CI
MIFH
LIM
UBS Group's TEVA Position: Q1 2026 in Review
UBS Group reduced its Teva Pharmaceuticals (TEVA) stake by 56% in Q1 2026, selling an estimated $77.2M and leaving 1,877,217 shares worth $56.5M. The position accounts for 0.01% of the portfolio, ranked #1527.
UBS Group first reported a position in TEVA in Q4 2014 and has held it in 46 quarters since. The position peaked at $134M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.
- UBS Group held 1,877,217 shares of Teva Pharmaceuticals worth $56.5M as of Q1 2026.
- UBS Group sold 2,400,769 Teva Pharmaceuticals shares in Q1 2026, an estimated $77.2M.
- Teva Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1527 holding.
- UBS Group first reported a position in Teva Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Teva Pharmaceuticals position peaked at $134M in Q4 2025.
- 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.